Clinical trial
M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in…
NCT00477906 · AVAX Technologies, Industry · Unknown status
Key facts
| NCT number | NCT00477906 |
|---|---|
| Title | M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma |
| Official title | Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma |
| Lead sponsor | AVAX Technologies, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | M-Vax- autologous, hapten-modified melanoma vaccine |
| Enrollment | 387 |
| Start date | Jul 1, 2016 |
| Primary completion | Jan 1, 2019 |
| Completion | Jan 1, 2021 |
| First posted | May 24, 2007 |
| Last update posted | Dec 3, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: